Skip to Main Content

Paper Details

Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an -Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD.
Current Oncology
11
2021
CMMRD, Constitutional mismatch repair deficiency, DNA mismatch repair genes, IDH1, IDH1-Mutant Anaplastic Astrocytoma, PMS2 gene, Patient, adenocarcinoma of the colon, anaplastic astrocytoma, asymptomatic, autosomal recessive hereditary cancer syndrome, brain cancer, c.2002A, c.2002A>G, patient, patients
Author NameAffiliation
Uri TaboriThe Hospital for Sick Children, University of Toronto
  • 1 - 1

Datasets

Release 1.2